<p>Subgroups were stratified according to whether the non-platinum contained new-generation agents such as S-1, taxanes or irinotecan.</p
num analogue with a distinctively different toxicity profile from cisplatin, carboplatin has become ...
AIM: To assess CA-125 in defining tumor response in patients treated with paclitaxel. RESULS: CA-125...
BackgroundResponse criteria developed when cytotoxic chemotherapy was the predominant therapeutic mo...
<p>Subgroups were stratified according to whether the non-platinum contained new-generation agents s...
a<p>Almost all patients were treated with paclitaxel in the first-line chemotherapy, so the matched ...
<p>Comparison of objective response rate and toxicity in therapy subgroups by type of malignancy.</p
A comparison of platinum-based and non-platinum-based chemotherapy regimens for the treatment of sma...
<p>Meta-analysis of overall response rate for S-1-based chemotherapy compared with capecitabine-base...
Objectives: As suggested by in-vitro data, we hypothesize that subtypes of ICRAS mutated non-small c...
<p>Regions including bilateral fusiform, ipsilateral IPL and contralateral STG were more activated i...
Platinum complexes are among the most commonly applied anticancer agents. The aim of current work is...
<p>Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).</p
Platinum-containing complexes and nitrogen mustard derivatives are two drug families for cancer trea...
<p>The median <i>in vitro</i> inhibition rate of cancer cell growth by cisplatin, carboplatin, nedap...
<p>Comparison of sorafenib with other regimens for HCC patients in terms of overall response rate (O...
num analogue with a distinctively different toxicity profile from cisplatin, carboplatin has become ...
AIM: To assess CA-125 in defining tumor response in patients treated with paclitaxel. RESULS: CA-125...
BackgroundResponse criteria developed when cytotoxic chemotherapy was the predominant therapeutic mo...
<p>Subgroups were stratified according to whether the non-platinum contained new-generation agents s...
a<p>Almost all patients were treated with paclitaxel in the first-line chemotherapy, so the matched ...
<p>Comparison of objective response rate and toxicity in therapy subgroups by type of malignancy.</p
A comparison of platinum-based and non-platinum-based chemotherapy regimens for the treatment of sma...
<p>Meta-analysis of overall response rate for S-1-based chemotherapy compared with capecitabine-base...
Objectives: As suggested by in-vitro data, we hypothesize that subtypes of ICRAS mutated non-small c...
<p>Regions including bilateral fusiform, ipsilateral IPL and contralateral STG were more activated i...
Platinum complexes are among the most commonly applied anticancer agents. The aim of current work is...
<p>Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).</p
Platinum-containing complexes and nitrogen mustard derivatives are two drug families for cancer trea...
<p>The median <i>in vitro</i> inhibition rate of cancer cell growth by cisplatin, carboplatin, nedap...
<p>Comparison of sorafenib with other regimens for HCC patients in terms of overall response rate (O...
num analogue with a distinctively different toxicity profile from cisplatin, carboplatin has become ...
AIM: To assess CA-125 in defining tumor response in patients treated with paclitaxel. RESULS: CA-125...
BackgroundResponse criteria developed when cytotoxic chemotherapy was the predominant therapeutic mo...
DOI
Add to ORKG